Introduction
The aim of the study was to evaluate the efficacy and tolerability of a rifampicin-ofloxacin combination for treating diabetic patients with pedal osteomyelitis reliably documented by the culture of a surgical bone biopsy. These antibiotics were chosen because they are currently considered to be the most appropriate for the treatment of chronic osteomyelitis. 1 This is, to our knowledge, the first report of the use of this antibiotic combination in such patients.
Materials and methods
Patients included in this study were inpatients and outpatients with infected foot ulcers who attended a diabetes clinic in Northern France from December 1996 to June 1999. Osteomyelitis was suspected if two or more of the following criteria were fulfilled: history of a previous osteomyelitis, duration of Ͼ2 weeks, location (bony prominence), size (surface area Ͼ2 cm 2 , depth Ͼ3 mm), exposed bone, bone probe, erythrocyte sedimentation rate Ͼ 60 min. All enrolled patients underwent a radiographic and/or a scintigraphic investigation, followed by biopsy of the infected bony site(s). Scintigraphic investigations were performed using coupled gallium ( 67 Ga citrate)-technetium ( 99m Tc-diphosponate) radionuclide or Sulesomab scintigraphy (anti-granulocyte antibody FabЈ fragment labelled with 99m Tc). 2 The ulcer crater was swabbed following light cleansing of the ulcer with sterile saline. Surgical bone biopsies were performed using a 14-gauge trocar placed through a 5-10 mm incision in an area of skin at least 20 mm distant from the ulcer and through the dorsal face of the foot in the case of plantar ulcer(s). One bone fragment was put directly into Rosenow liquid medium (Bio-Rad, Marnes La Coquette, France) and another into standard brain-heart broth (bioMérieux, Marcy l'Étoile, France) and immediately transported to the laboratory where cultures were maintained for 2 weeks.
Study patients received ofloxacin 200 mg po tds with food and rifampicin 600 mg po bd 30 min before or 2 h after food. Antibiotic dosages and duration were adapted from the French guidelines for treating chronic osteomyelitis. 3 High doses of ofloxacin (i.e. 400 mg bd) were not used because they are not always tolerated by the elderly. We used a tds regimen to avoid the low blood levels observed in some patients due to inter-individual differences in fluoroquinolone metabolism. 4 Initial iv administration of the study treatment was accepted. 
Rifampicin-ofloxacin oral regimen
evaluation were permitted to stop the treatment, although they were encouraged to complete 6 months of treatment.
The primary outcome of the study was clinical response defined as cure (disappearance of all signs and symptoms associated with the initial ulcer at the end of the treatment and no relapse occurring during the post-treatment followup period) or failure (any other outcome). Relapse and superinfection were defined as appearance of an active infection at the site of the initial infection or contiguous to it due to a pathogen identical to or different from the pathogen isolated at enrolment in the study, respectively. Bone scan assessment was graded as: significant improvement or normalization of the bone uptake, no improvement or deterioration. After hospital discharge, patients were followed up at 3 and 6 months by the infectious diseases consultant and monthly by the endocrinologist.
Patients with infections caused by pathogens resistant to rifampicin or ofloxacin were excluded from the study.
Results and discussion
Pedal osteomyelitis was confirmed by the results of both bone scan and biopsy in 31 of the 130 diabetic patients (23.8%) with an infected foot lesion who attended our clinic. Among them, 17 patients with 20 osteomyelitic bones were treated with the combination of rifampicin and ofloxacin, and these constituted the study population.
The median age of the study patients was 62 years (range 51-77 years) and 13 (76.5%) were male; all patients had non-insulin-dependent diabetes mellitus with a median duration of 16 years (range 9-30 years). Most foot lesions (15/20) were graded with a Wagner score of 3 (Table 1) . Only one patient had fever at entry (patient 9). Fifteen patients underwent plain radiographs of the foot, among which 12 were abnormal, showing bone demineralization in 10 cases and a cortical defect in two cases.
Gram-positive cocci accounted for Ͼ85% of the pathogens isolated from both the ulcer and the bone samples. When comparing the cultures of superficial swabbing and bone biopsy obtained from the same infectious site, identical results were noted in only 4/14 evaluable cases (28.6%). Coagulase-negative staphylococci (CNS) were not cultured from swabs although they were found in eight bone biopsies (P Ͻ 0.01), which is likely to be related to the nonreport of CNS from superficial samples by our laboratory. Patients with infections caused by Streptococcus spp. and Corynebacterium spp. with intermediate susceptibility to ofloxacin were entered into the study because its bone/blood concentration is high (Table 2) . 4, 5 The median duration of the antimicrobial therapy was 6 months (range 3-10 months). Treatment was initially administered iv in five patients for a median duration of 5.5 days (range 3-17 days). Adjunctive surgery consisting of necrotic bone resection was performed in two patients. The median hospital stay duration was 14 days (range 3-53 days), which The absence of CNS in the swabbing culture is probably related to the non-report of these bacteria in superficial samples by the laboratory.
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is shorter than reported in other studies. 6 This might be related to the high bioavailability of the study treatment, which allowed a prompt switch to oral treatment.
After 3 and 6 months treatment, 15/17 (88.2%) and 12/14 evaluable patients (85.7%), respectively, were cured, which is comparable to previous studies. 7 However, cure was maintained in 13 patients (76.5%) for a median period of 22 months (range 12-41 months) following the end of treatment, which is the delay usually reported to correctly assess the outcome of patients with chronic osteomyelitis. 8 Two patients with staphylococcal osteomyelitis (patients 8 and 17) failed to respond to the study treatment. The control of the vascular status of these two patients did not show any severe arterial obstructive lesion.
At entry, coupled gallium-technetium bone scan performed in four patients and Sulesomab-technetium performed in the 13 remaining patients showed marked bone uptake consistent with the diagnosis of osteomyelitis. The overall number of improved or normalized bone scans at the end of treatment was 16/17 (94%). Clinical and scintigraphic assessment of the osteomyelitis outcome was concordant in 16 of the 17 episodes for which the comparison was feasible. No adverse events were reported in the 13 patients who underwent repeated Sulesomab scintigraphies.
Fifteen adverse effects, predominantly gastrointestinal and neurological, were reported in nine patients (47%), related to rifampicin and ofloxacin respectively, but did not require the discontinuation of the study treatment. Rifampicin dosage was reduced by 50% in four patients because of nausea. Three patients (3, 7 and 10) died of causes unrelated to the foot infection during the study. The isolation of multi-resistant bacteria in four patients might be the result of prolonged antibiotic therapy and could argue for shorter courses of treatment such as 3 months or less. 
